Application of microRNAs in diagnosis and treatment of cardiovascular disease

Acta Physiologica

Volumn 213, Issue 1, 2015, Pages 60-83

  Wronska, A ^a   Kurkowska Jastrzebska, I ^b,c   Santulli, G ^a  

^a College of Physicians and Surgeons of Columbia University ^*  (United States)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

atherosclerosis; biomarkers; cardiovascular disease; microRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MESSENGER RNA;

CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; GENE CONTROL; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; RNA, MESSENGER;

EID: 84923642690     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12416     Document Type: Review

References (173)

1. Abraham, W.T., Gilbert, E.M., Lowes, B.D., Minobe, W.A., Larrabee, P., Roden, R.L., Dutcher, D., Sederberg, J., Lindenfeld, J.A., Wolfel, E.E. et al. 2002. Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med 8, 750–760.
2. Adam, O., Lohfelm, B., Thum, T., Gupta, S.K., Puhl, S.L., Schafers, H.J., Bohm, M. & Laufs, U. 2012. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol, 107, 1–12.
3. Ai, J., Zhang, R., Li, Y., Pu, J., Lu, Y., Jiao, J., Li, K., Yu, B., Li, Z., Wang, R. et al. 2010. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 391, 73–77.
4. Arroyo, J.D., Chevillet, J.R., Kroh, E.M., Ruf, I.K., Pritchard, C.C., Gibson, D.F., Mitchell, P.S., Bennett, C.F., Pogosova-Agadjanyan, E.L., Stirewalt, D.L., Tait, J.F. & Tewari, M. 2011. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 108, 5003–5008.
5. Bang, O.Y., Lee, J.S., Lee, P.H. & Lee, G. 2005. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 57, 874–882.
6. Bauters, C., Kumarswamy, R., Holzmann, A., Bretthauer, J., Anker, S.D., Pinet, F. & Thum, T. 2013. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol 168, 1837–1840.
7. Bernardo, B.C., Gao, X.M., Winbanks, C.E., Boey, E.J., Tham, Y.K., Kiriazis, H., Gregorevic, P., Obad, S., Kauppinen, S., Du, X.J., Lin, R.C. & McMullen, J.R. 2012. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci USA 109, 17615–17620.
8. Blann, A.D., Belgore, F.M., McCollum, C.N., Silverman, S., Lip, P.L. & Lip, G.Y. 2002. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) 102, 187–194.
9. Boon, R.A. & Vickers, K.C. 2013. Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol 33, 186–192.
10. Bostjancic, E., Zidar, N., Stajer, D. & Glavac, D. 2010. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 115, 163–169.
11. Bostjancic, E., Zidar, N. & Glavac, D. 2012. MicroRNAs and cardiac sarcoplasmic reticulum calcium ATPase-2 in human myocardial infarction: expression and bioinformatic analysis. BMC Genom 13, 552.
12. Brennecke, J., Stark, A., Russell, R.B. & Cohen, S.M. 2005. Principles of microRNA-target recognition. PLoS Biol 3, e85.
13. Brown, J.H., Del Re, D.P. & Sussman, M.A. 2006. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98, 730–742.
14. Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.L., Segnalini, P., Gu, Y., Dalton, N.D. et al. 2007. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13, 613–618.
15. Carpinella, G., Pagano, G., Buono, F., Petitto, M., Guarino, G., Orefice, G., Rengo, G., Trimarco, B. & Morisco, C. 2014. Prognostic value of combined target-organ damage in patients with essential hypertension. Am J Hypertens doi: 10.1093/ajh/hpu098.
16. Ceolotto, G., Papparella, I., Bortoluzzi, A., Strapazzon, G., Ragazzo, F., Bratti, P., Fabricio, A.S., Squarcina, E., Gion, M., Palatini, P. & Semplicini, A. 2011. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens 24, 241–246.
17. Chavali, S., Bruhn, S., Tiemann, K., Saetrom, P., Barrenas, F., Saito, T., Kanduri, K., Wang, H. & Benson, M. 2013. MicroRNAs act complementarily to regulate disease-related mRNA modules in human diseases. RNA 19, 1552–1562.
18. Chen, J., Li, Y., Wang, L., Zhang, Z., Lu, D., Lu, M. & Chopp, M. 2001. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 32, 1005–1011.
19. Chen, J.F., Mandel, E.M., Thomson, J.M., Wu, Q., Callis, T.E., Hammond, S.M., Conlon, F.L. & Wang, D.Z. 2006. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38, 228–233.
20. Chen, J., Venkat, P., Zacharek, A. & Chopp, M. 2014. Neurorestorative therapy for stroke. Front Hum Neurosci 8, 382.
21. Chion, C.K., Doggen, C.J., Crawley, J.T., Lane, D.A. & Rosendaal, F.R. 2007. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109, 1998–2000.
22. Cipollone, F., Felicioni, L., Sarzani, R., Ucchino, S., Spigonardo, F., Mandolini, C., Malatesta, S., Bucci, M., Mammarella, C., Santovito, D., de Lutiis, F., Marchetti, A., Mezzetti, A. & Buttitta, F. 2011. A unique microRNA signature associated with plaque instability in humans. Stroke 42, 2556–2563.
23. Concepcion, C.P., Han, Y.C., Mu, P., Bonetti, C., Yao, E., D'Andrea, A., Vidigal, J.A., Maughan, W.P., Ogrodowski, P. & Ventura, A. 2012. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet 8, e1002797.
24. Corsten, M.F., Dennert, R., Jochems, S., Kuznetsova, T., Devaux, Y., Hofstra, L., Wagner, D.R., Staessen, J.A., Heymans, S. & Schroen, B. 2010. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 3, 499–506.
25. da Costa Martins, P.A., Salic, K., Gladka, M.M., Armand, A.S., Leptidis, S., el Azzouzi, H., Hansen, A., Coenen-de Roo, C.J., Bierhuizen, M.F., van der Nagel, R. et al. 2010. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol, 12, 1220–1227.
26. D'Ascia, S.L., D'Ascia, C., Marino, V., Lombardi, A., Santulli, R., Chiariello, M. & Santulli, G. 2011. Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in non-ischaemic dilated cardiomyopathy. Int J Clin Pract 65, 1149–1155.
27. Dawson, K., Wakili, R., Ordog, B., Clauss, S., Chen, Y., Iwasaki, Y., Voigt, N., Qi, X.Y., Sinner, M.F., Dobrev, D., Kaab, S. & Nattel, S. 2013. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation, 127, 1466–1475, 1475e1–28.
28. Devlin, C., Greco, S., Martelli, F. & Ivan, M. 2011. miR-210: more than a silent player in hypoxia. IUBMB Life 63, 94–100.
29. Dharap, A., Bowen, K., Place, R., Li, L.C. & Vemuganti, R. 2009. Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome. J Cereb Blood Flow Metab 29, 675–687.
30. Dickinson, B.A., Semus, H.M., Montgomery, R.L., Stack, C., Latimer, P.A., Lewton, S.M., Lynch, J.M., Hullinger, T.G., Seto, A.G. & van Rooij, E. 2013. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail 15, 650–659.
31. Dimmeler, S. & Nicotera, P. 2013. MicroRNAs in age-related diseases. EMBO Mol Med 5, 180–190.
32. Dirkx, E., da Costa Martins, P.A. & De Windt, L.J. 2013. Regulation of fetal gene expression in heart failure. Biochim Biophys Acta, 1832, 2414–2424.
33. Dong, S., Cheng, Y., Yang, J., Li, J., Liu, X., Wang, X., Wang, D., Krall, T.J., Delphin, E.S. & Zhang, C. 2009. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 284, 29514–29525.
34. Doris, P.A. 2002. Hypertension genetics, single nucleotide polymorphisms, and the common disease:common variant hypothesis. Hypertension 39, 323–331.
35. Duisters, R.F., Tijsen, A.J., Schroen, B., Leenders, J.J., Lentink, V., van der Made, I., Herias, V., van Leeuwen, R.E., Schellings, M.W., Barenbrug, P., Maessen, J.G., Heymans, S., Pinto, Y.M. & Creemers, E.E. 2009. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res, 104, 170–178, 6p following 178.
36. Ehrlich, J.R. 2008. Inward rectifier potassium currents as a target for atrial fibrillation therapy. J Cardiovasc Pharmacol 52, 129–135.
37. Ellis, K.L., Cameron, V.A., Troughton, R.W., Frampton, C.M., Ellmers, L.J. & Richards, A.M. 2013. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 15, 1138–1147.
38. Eskildsen, T.V., Jeppesen, P.L., Schneider, M., Nossent, A.Y., Sandberg, M.B., Hansen, P.B., Jensen, C.H., Hansen, M.L., Marcussen, N., Rasmussen, L.M., Bie, P., Andersen, D.C. & Sheikh, S.P. 2013. Angiotensin II regulates microRNA-132/-212 in hypertensive rats and humans. Int J Mol Sci 14, 11190–11207.
39. Fichtlscherer, S., De Rosa, S., Fox, H., Schwietz, T., Fischer, A., Liebetrau, C., Weber, M., Hamm, C.W., Roxe, T., Muller-Ardogan, M., Bonauer, A., Zeiher, A.M. & Dimmeler, S. 2010. Circulating microRNAs in patients with coronary artery disease. Circ Res 107, 677–684.
40. Figueira, M.F., Monnerat-Cahli, G., Medei, E., Carvalho, A.B., Morales, M.M., Lamas, M.E., da Fonseca, R.N. & Souza-Menezes, J. 2014. MicroRNAs: potential therapeutic targets in diabetic complications of the cardiovascular and renal systems. Acta Physiol (Oxf) 211, 491–500.
41. Fish, J.E., Santoro, M.M., Morton, S.U., Yu, S., Yeh, R.F., Wythe, J.D., Ivey, K.N., Bruneau, B.G., Stainier, D.Y. & Srivastava, D. 2008. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15, 272–284.
42. Friedman, Y., Balaga, O. & Linial, M. 2013. Working together: combinatorial regulation by microRNAs. Adv Exp Med Biol 774, 317–337.
43. Frost, R.J. & van Rooij, E. 2010. miRNAs as therapeutic targets in ischemic heart disease. J Cardiovasc Transl Res 3, 280–289.
44. Gaziano, T.A., Bitton, A., Anand, S., Abrahams-Gessel, S. & Murphy, A. 2010. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 35, 72–115.
45. Girmatsion, Z., Biliczki, P., Bonauer, A., Wimmer-Greinecker, G., Scherer, M., Moritz, A., Bukowska, A., Goette, A., Nattel, S., Hohnloser, S.H. & Ehrlich, J.R. 2009. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm 6, 1802–1809.
46. Goldraich, L.A., Martinelli, N.C., Matte, U., Cohen, C., Andrades, M., Pimentel, M., Biolo, A., Clausell, N. & Rohde, L.E. 2014. Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression. Biomarkers 19, 135–141.
47. Goren, Y., Kushnir, M., Zafrir, B., Tabak, S., Lewis, B.S. & Amir, O. 2012. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 14, 147–154.
48. Greco, S., Fasanaro, P., Castelvecchio, S., D'Alessandra, Y., Arcelli, D., Di Donato, M., Malavazos, A., Capogrossi, M.C., Menicanti, L. & Martelli, F. 2012. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 61, 1633–1641.
49. Guo, X., Barroso, L., Lyerly, D.M., Petri, W.A. Jr & Houpt, E.R. 2011. CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine. Vaccine 29, 772–777.
50. Hale, C.S. & Levis, W.R. 2013. MicroRNA-29 and an integrated understanding of atrial fibrillation. J Drugs Dermatol 12, 1083.
51. Han, L., Witmer, P.D., Casey, E., Valle, D. & Sukumar, S. 2007. DNA methylation regulates MicroRNA expression. Cancer Biol Ther 6, 1284–1288.
52. Harris, T.A., Yamakuchi, M., Ferlito, M., Mendell, J.T. & Lowenstein, C.J. 2008. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 105, 1516–1521.
53. Heather, L.C. & Clarke, K. 2011. Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol 50, 598–605.
54. Hindorff, L.A., Heckbert, S.R., Tracy, R., Tang, Z., Psaty, B.M., Edwards, K.L., Siscovick, D.S., Kronmal, R.A. & Nazar-Stewart, V. 2002. Angiotensin II type 1 receptor polymorphisms in the cardiovascular health study: relation to blood pressure, ethnicity, and cardiovascular events. Am J Hypertens 15, 1050–1056.
55. Hoekstra, M., van der Lans, C.A., Halvorsen, B., Gullestad, L., Kuiper, J., Aukrust, P., van Berkel, T.J. & Biessen, E.A. 2010. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun 394, 792–797.
56. Holland, R.P. & Brooks, H. 1976. The QRS complex during myocardial ischemia. An experimental analysis in the porcine heart. J Clin Invest 57, 541–550.
57. Huang, F., Zhu, X., Hu, X.Q., Fang, Z.F., Tang, L., Lu, X.L. & Zhou, S.H. 2013. Mesenchymal stem cells modified with miR-126 release angiogenic factors and activate Notch ligand Delta-like-4, enhancing ischemic angiogenesis and cell survival. Int J Mol Med 31, 484–492.
58. Icli, B., Wara, A.K., Moslehi, J., Sun, X., Plovie, E., Cahill, M., Marchini, J.F., Schissler, A., Padera, R.F., Shi, J. et al. 2013. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res 113, 1231–1241.
59. Icli, B., Dorbala, P. & Feinberg, M.W. 2014. An emerging role for the miR-26 family in cardiovascular disease. Trends Cardiovasc Med. doi: 10.1016/j.tcm.2014.06.003.
60. Ikeda, S., Kong, S.W., Lu, J., Bisping, E., Zhang, H., Allen, P.D., Golub, T.R., Pieske, B. & Pu, W.T. 2007. Altered microRNA expression in human heart disease. Physiol Genomics 31, 367–373.
61. Ivey, K.N., Muth, A., Arnold, J., King, F.W., Yeh, R.F., Fish, J.E., Hsiao, E.C., Schwartz, R.J., Conklin, B.R., Bernstein, H.S. & Srivastava, D. 2008. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell 2, 219–229.
62. Jakob, P., Doerries, C., Briand, S., Mocharla, P., Krankel, N., Besler, C., Mueller, M., Manes, C., Templin, C., Baltes, C. et al. 2012. Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in vivo neovascularization and cardiac repair capacity. Circulation 126, 2962–2975.
63. Janssen, H.L., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A.J., Patick, A.K., Chen, A., Zhou, Y., Persson, R., King, B.D., Kauppinen, S., Levin, A.A. & Hodges, M.R. 2013. Treatment of HCV infection by targeting microRNA. N Engl J Med 368, 1685–1694.
64. Karakikes, I., Chaanine, A.H., Kang, S., Mukete, B.N., Jeong, D., Zhang, S., Hajjar, R.J. & Lebeche, D. 2013. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2, e000078.
65. Karolina, D.S., Tavintharan, S., Armugam, A., Sepramaniam, S., Pek, S.L., Wong, M.T., Lim, S.C., Sum, C.F. & Jeyaseelan, K. 2012. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 97, E2271–E2276.
66. Kato, M., Castro, N.E. & Natarajan, R. 2013. MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med 64, 85–94.
67. Kawamoto, A., Gwon, H.C., Iwaguro, H., Yamaguchi, J.I., Uchida, S., Masuda, H., Silver, M., Ma, H., Kearney, M., Isner, J.M. & Asahara, T. 2001. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103, 634–637.
68. Kin, K., Miyagawa, S., Fukushima, S., Shirakawa, Y., Torikai, K., Shimamura, K., Daimon, T., Kawahara, Y., Kuratani, T. & Sawa, Y. 2012. Tissue- and plasma-specific MicroRNA signatures for atherosclerotic abdominal aortic aneurysm. J Am Heart Assoc 1, e000745.
69. Kishore, A., Borucka, J., Petrkova, J. & Petrek, M. 2014. Novel insights into miRNA in lung and heart inflammatory diseases. Mediators Inflamm 2014, 259131.
70. Knoll, R., Iaccarino, G., Tarone, G., Hilfiker-Kleiner, D., Bauersachs, J., Leite-Moreira, A.F., Sugden, P.H. & Balligand, J.L. 2011. Towards a re-definition of ‘cardiac hypertrophy’ through a rational characterization of left ventricular phenotypes: a position paper of the Working Group ‘Myocardial Function’ of the ESC. Eur J Heart Fail 13, 811–819.
71. Kocher, A.A., Schuster, M.D., Szabolcs, M.J., Takuma, S., Burkhoff, D., Wang, J., Homma, S., Edwards, N.M. & Itescu, S. 2001. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7, 430–436.
72. Kontaraki, J.E., Marketou, M.E., Zacharis, E.A., Parthenakis, F.I. & Vardas, P.E. 2014a. Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension. J Hum Hypertens 28, 510–516.
73. Kontaraki, J.E., Marketou, M.E., Zacharis, E.A., Parthenakis, F.I. & Vardas, P.E. 2014b. MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage. J Am Soc Hypertens 8, 368–375.
74. Kucukardali, Y., Aydogdu, S., Ozmen, N., Yonem, A., Solmazgul, E., Ozyurt, M., Cingozbay, Y. & Aydogdu, A. 2008. The relationship between severity of coronary artery disease and plasma level of vascular endothelial growth factor. Cardiovasc Revasc Med 9, 66–70.
75. Kumar, R., Kohli, S., Mishra, A., Garg, R., Alam, P., Stobdan, T., Nejatizadeh, A., Gupta, M., Tyagi, S. & Pasha, M.A. 2014. Interactions between the genes of vasodilatation pathways influence blood pressure and nitric oxide level in hypertension. Am J Hypertens. doi: 10.1093/ajh/hpu130.
76. Latronico, M.V. & Condorelli, G. 2011. microRNAs in hypertrophy and heart failure. Exp Biol Med (Maywood) 236, 125–131.
77. Lee, R.C., Feinbaum, R.L. & Ambros, V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843–854.
78. Lee, J.S., Hong, J.M., Moon, G.J., Lee, P.H., Ahn, Y.H. & Bang, O.Y. 2010. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 28, 1099–1106.
79. Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P. & Burge, C.B. 2003. Prediction of mammalian microRNA targets. Cell 115, 787–798.
80. Li, K., Zhang, T., Fan, H., Li, Q., Ito, W., Torzewski, J., Guo, J. & Liu, Z. 2014a. The analysis of microRNA expression profiling for coronary artery disease. Cardiology 127, 62–69.
81. Li, Y., Liu, Z., Xin, H. & Chopp, M. 2014b. The role of astrocytes in mediating exogenous cell-based restorative therapy for stroke. Glia 62, 1–16.
82. Liu, N., Williams, A.H., Kim, Y., McAnally, J., Bezprozvannaya, S., Sutherland, L.B., Richardson, J.A., Bassel-Duby, R. & Olson, E.N. 2007. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci USA 104, 20844–20849.
83. Liu, N., Bezprozvannaya, S., Williams, A.H., Qi, X., Richardson, J.A., Bassel-Duby, R. & Olson, E.N. 2008. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 22, 3242–3254.
84. Liu, G., Friggeri, A., Yang, Y., Park, Y.J., Tsuruta, Y. & Abraham, E. 2009. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci USA 106, 15819–15824.
85. Lowes, B.D., Gilbert, E.M., Abraham, W.T., Minobe, W.A., Larrabee, P., Ferguson, D., Wolfel, E.E., Lindenfeld, J., Tsvetkova, T., Robertson, A.D., Quaife, R.A. & Bristow, M.R. 2002. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346, 1357–1365.
86. Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., Zhang, Y., Shan, H., Luo, X., Bai, Y., Sun, L., Song, W., Xu, C., Wang, Z. & Yang, B. 2010. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 122, 2378–2387.
87. Lwin, T., Zhao, X., Cheng, F., Zhang, X., Huang, A., Shah, B., Zhang, Y., Moscinski, L.C., Choi, Y.S., Kozikowski, A.P., Bradner, J.E., Dalton, W.S., Sotomayor, E. & Tao, J. 2013. A microenvironment-mediated c-Myc/miR-548 m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest 123, 4612–4626.
88. Mak, K.H., Moliterno, D.J., Granger, C.B., Miller, D.P., White, H.D., Wilcox, R.G., Califf, R.M. & Topol, E.J. 1997. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 30, 171–179.
89. Margulies, K.B., Matiwala, S., Cornejo, C., Olsen, H., Craven, W.A. & Bednarik, D. 2005. Mixed messages: transcription patterns in failing and recovering human myocardium. Circ Res 96, 592–599.
90. Matkovich, S.J., Van Booven, D.J., Youker, K.A., Torre-Amione, G., Diwan, A., Eschenbacher, W.H., Dorn, L.E., Watson, M.A., Margulies, K.B. & Dorn, G.W. 2nd 2009. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 119, 1263–1271.
91. Mauric, A.T. & Oreto, G. 2008. STEMI or NSTEMI, i.e. ST-evaluation or non-ST-evaluation myocardial infarction? J Cardiovasc Med (Hagerstown) 9, 81–82.
92. Meijs, M.F., de Windt, L.J., de Jonge, N., Cramer, M.J., Bots, M.L., Mali, W.P. & Doevendans, P.A. 2007. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 14, 157–171.
93. Minami, Y., Satoh, M., Maesawa, C., Takahashi, Y., Tabuchi, T., Itoh, T. & Nakamura, M. 2009. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest 39, 359–367.
94. Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J., O'Briant, K.C., Allen, A. et al. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105, 10513–10518.
95. Moniche, F., Gonzalez, A., Gonzalez-Marcos, J.R., Carmona, M., Pinero, P., Espigado, I., Garcia-Solis, D., Cayuela, A., Montaner, J., Boada, C., Rosell, A., Jimenez, M.D., Mayol, A. & Gil-Peralta, A. 2012. Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke 43, 2242–2244.
96. Naga Prasad, S.V., Duan, Z.H., Gupta, M.K., Surampudi, V.S., Volinia, S., Calin, G.A., Liu, C.G., Kotwal, A., Moravec, C.S., Starling, R.C. et al. 2009. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem 284, 27487–27499.
97. Nagai, R., Shindo, T., Manabe, I., Suzuki, T. & Kurabayashi, M. 2003. KLF5/BTEB2, a Kruppel-like zinc-finger type transcription factor, mediates both smooth muscle cell activation and cardiac hypertrophy. Adv Exp Med Biol, 538, 57–65; discussion 66.
98. Natarajan, R., Putta, S. & Kato, M. 2012. MicroRNAs and diabetic complications. J Cardiovasc Transl Res 5, 413–422.
99. Nattel, S. 2002. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res 54, 347–360.
100. Navarro, A., Diaz, T., Martinez, A., Gaya, A., Pons, A., Gel, B., Codony, C., Ferrer, G., Martinez, C., Montserrat, E. & Monzo, M. 2009. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 114, 2945–2951.
101. Nilsson, J., Wigren, M. & Shah, P.K. 2009. Regulatory T cells and the control of modified lipoprotein autoimmunity-driven atherosclerosis. Trends Cardiovasc Med 19, 272–276.
102. Norata, G.D., Sala, F., Catapano, A.L. & Fernandez-Hernando, C. 2013. MicroRNAs and lipoproteins: a connection beyond atherosclerosis? Atherosclerosis 227, 209–215.
103. Nossent, A.Y., Hansen, J.L., Doggen, C., Quax, P.H., Sheikh, S.P. & Rosendaal, F.R. 2011. SNPs in microRNA binding sites in 3′-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am J Hypertens 24, 999–1006.
104. Olivieri, F., Antonicelli, R., Lorenzi, M., D'Alessandra, Y., Lazzarini, R., Santini, G., Spazzafumo, L., Lisa, R., La Sala, L., Galeazzi, R., Recchioni, R., Testa, R., Pompilio, G., Capogrossi, M.C. & Procopio, A.D. 2013. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol 167, 531–536.
105. Olson, E.N. 2014. MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med 6, 239 ps3.
106. Ono, K., Kuwabara, Y. & Han, J. 2011. MicroRNAs and cardiovascular diseases. FEBS J 278, 1619–1633.
107. Ouyang, Y.B. & Giffard, R.G. 2013. microRNAs affect BCL-2 family proteins in the setting of cerebral ischemia. Neurochem Int 77, 2–8.
108. Parving, H.H., Brenner, B.M., McMurray, J.J., de Zeeuw, D., Haffner, S.M., Solomon, S.D., Chaturvedi, N., Persson, F., Desai, A.S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P. & Pfeffer, M.A. 2012. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367, 2204–2213.
109. Periasamy, M., Bhupathy, P. & Babu, G.J. 2008. Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology. Cardiovasc Res 77, 265–273.
110. Piras, B.A., O'Connor, D.M. & French, B.A. 2013. Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver. PLoS ONE 8, e75894.
111. Poirier, O., Georges, J.L., Ricard, S., Arveiler, D., Ruidavets, J.B., Luc, G., Evans, A., Cambien, F. & Tiret, L. 1998. New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: the ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde. J Hypertens 16, 1443–1447.
112. van der Pouw Kraan, T.C., Bernink, F.J., Yildirim, C., Koolwijk, P., Baggen, J.M., Timmers, L., Beek, A.M., Diamant, M., Chen, W.J., van Rossum, A.C., van Royen, N., Horrevoets, A.J. & Appelman, Y.E. 2014. Systemic toll-like receptor and interleukin-18 pathway activation in patients with acute ST elevation myocardial infarction. J Mol Cell Cardiol 67, 94–102.
113. Raitoharju, E., Lyytikainen, L.P., Levula, M., Oksala, N., Mennander, A., Tarkka, M., Klopp, N., Illig, T., Kahonen, M., Karhunen, P.J., Laaksonen, R. & Lehtimaki, T. 2011. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 219, 211–217.
114. Ranjha, R. & Paul, J. 2013. Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer. Inflamm Res 62, 343–355.
115. Rao, P.K., Toyama, Y., Chiang, H.R., Gupta, S., Bauer, M., Medvid, R., Reinhardt, F., Liao, R., Krieger, M., Jaenisch, R., Lodish, H.F. & Blelloch, R. 2009. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 105, 585–594.
116. Rink, C. & Khanna, S. 2011. MicroRNA in ischemic stroke etiology and pathology. Physiol Genomics 43, 521–528.
117. Robbins, C.S., Hilgendorf, I., Weber, G.F., Theurl, I., Iwamoto, Y., Figueiredo, J.L., Gorbatov, R., Sukhova, G.K., Gerhardt, L.M., Smyth, D. et al. 2013. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 19, 1166–1172.
118. van Rooij, E. & Olson, E.N. 2012. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 11, 860–872.
119. van Rooij, E., Sutherland, L.B., Liu, N., Williams, A.H., McAnally, J., Gerard, R.D., Richardson, J.A. & Olson, E.N. 2006. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103, 18255–18260.
120. van Rooij, E., Quiat, D., Johnson, B.A., Sutherland, L.B., Qi, X., Richardson, J.A., Kelm, R.J. Jr & Olson, E.N. 2009. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 17, 662–673.
121. van Rooij, E., Purcell, A.L. & Levin, A.A. 2012. Developing microRNA therapeutics. Circ Res 110, 496–507.
122. Sandercock, P., Lindley, R., Wardlaw, J., Dennis, M., Innes, K., Cohen, G., Whiteley, W., Perry, D., Soosay, V., Buchanan, D. et al. 2011. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials 12, 252.
123. Santoro, M.M. 2011. “Fishing” for endothelial microRNA functions and dysfunction. Vascul Pharmacol 55, 60–68.
124. Santulli, G. 2012. Coronary heart disease risk factors and mortality. JAMA, 307, 1137; author reply 1138.
125. Santulli, G., Cipolletta, E., Sorriento, D., Del Giudice, C., Anastasio, A., Monaco, S., Maione, A.S., Condorelli, G., Puca, A., Trimarco, B., Illario, M. & Iaccarino, G. 2012. CaMK4 gene deletion induces hypertension. J Am Heart Assoc 1, e001081.
126. Santulli, G., Trimarco, B. & Iaccarino, G. 2013. G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms. High Blood Press Cardiovasc Prev 20, 5–12.
127. Santulli, G., Iaccarino, G., De Luca, N., Trimarco, B. & Condorelli, G. 2014a. Atrial fibrillation and microRNAs. Front Physiol 5, 15.
128. Santulli, G., Wronska, A., Kunihiro, U., Diacovo, T., Gao, M., Marx, S., Kitajewski, J., Chilton, J., Kemal, M., Tuschl, T., Marks, A.R. & Totary Jain, H. 2014b. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest 124, 4102–4114.
129. Satoh, M., Shimoda, Y., Akatsu, T., Ishikawa, Y., Minami, Y. & Nakamura, M. 2006. Elevated circulating levels of heat shock protein 70 are related to systemic inflammatory reaction through monocyte Toll signal in patients with heart failure after acute myocardial infarction. Eur J Heart Fail 8, 810–815.
130. Satoh, M., Minami, Y., Takahashi, Y., Tabuchi, T. & Nakamura, M. 2010. Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail 16, 404–410.
131. Schivo, M., Aksenov, A.A., Yeates, L.C., Pasamontes, A. & Davis, C.E. 2013. Diabetes and the metabolic syndrome: possibilities of a new breath test in a dolphin model. Front Endocrinol (Lausanne) 4, 163.
132. Sepramaniam, S., Tan, J.R., Tan, K.S., Desilva, D.A., Tavintharan, S., Woon, F.P., Wang, C.W., Yong, F.L., Karolina, D.S., Kaur, P., Liu, F.J., Lim, K.Y., Armugam, A. & Jeyaseelan, K. 2014. Circulating microRNAs as biomarkers of acute stroke. Int J Mol Sci 15, 1418–1432.
133. Sethupathy, P., Borel, C., Gagnebin, M., Grant, G.R., Deutsch, S., Elton, T.S., Hatzigeorgiou, A.G. & Antonarakis, S.E. 2007. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 81, 405–413.
134. Sharma, S., Jackson, P.G. & Makan, J. 2004. Cardiac troponins. J Clin Pathol 57, 1025–1026.
135. Shigoka, M., Tsuchida, A., Matsudo, T., Nagakawa, Y., Saito, H., Suzuki, Y., Aoki, T., Murakami, Y., Toyoda, H., Kumada, T. et al. 2010. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 60, 351–357.
136. Sorriento, D., Ciccarelli, M., Santulli, G., Campanile, A., Altobelli, G.G., Cimini, V., Galasso, G., Astone, D., Piscione, F., Pastore, L., Trimarco, B. & Iaccarino, G. 2008. The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha. Proc Natl Acad Sci USA 105, 17818–17823.
137. Stary, C.M. & Giffard, R.G. 2014. Advances in astrocyte-targeted approaches for stroke therapy: an emerging role for mitochondria and microRNAS. Neurochem Res. doi: 10.1007/s11064-014-1373-4.
138. Stone, P.H., Muller, J.E., Hartwell, T., York, B.J., Rutherford, J.D., Parker, C.B., Turi, Z.G., Strauss, H.W., Willerson, J.T., Robertson, T. et al. 1989. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 14, 49–57.
139. Suarez-Monteagudo, C., Hernandez-Ramirez, P., Alvarez-Gonzalez, L., Garcia-Maeso, I., de la Cuetara-Bernal, K., Castillo-Diaz, L., Bringas-Vega, M.L., Martinez-Aching, G., Morales-Chacon, L.M., Baez-Martin, M.M. et al. 2009. Autologous bone marrow stem cell neurotransplantation in stroke patients. An open study. Restor Neurol Neurosci 27, 151–161.
140. Sucharov, C., Bristow, M.R. & Port, J.D. 2008. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 45, 185–192.
141. Sun, X., He, S., Wara, A.K., Icli, B., Shvartz, E., Tesmenitsky, Y., Belkin, N., Li, D., Blackwell, T.S., Sukhova, G.K., Croce, K. & Feinberg, M.W. 2014a. Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 114, 32–40.
142. Sun, X., Sit, A. & Feinberg, M.W. 2014b. Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc Med 24, 105–112.
143. Taganov, K.D., Boldin, M.P., Chang, K.J. & Baltimore, D. 2006. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103, 12481–12486.
144. Takahashi, Y., Satoh, M., Minami, Y., Tabuchi, T., Itoh, T. & Nakamura, M. 2010. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci (Lond) 119, 395–405.
145. Tan, J.R., Tan, K.S., Koo, Y.X., Yong, F.L., Wang, C.W., Armugam, A. & Jeyaseelan, K. 2013. Blood microRNAs in low or no risk ischemic stroke patients. Int J Mol Sci 14, 2072–2084.
146. Thum, T. 2008. Cardiac dissonance without conductors: how dicer depletion provokes chaos in the heart. Circulation 118, 1524–1527.
147. Thum, T., Galuppo, P., Wolf, C., Fiedler, J., Kneitz, S., van Laake, L.W., Doevendans, P.A., Mummery, C.L., Borlak, J., Haverich, A., Gross, C., Engelhardt, S., Ertl, G. & Bauersachs, J. 2007. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116, 258–267.
148. Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S. et al. 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980–984.
149. Thygesen, K., Alpert, J.S. & White, H.D. 2007. Universal definition of myocardial infarction. Eur Heart J 28, 2525–2538.
150. Tijsen, A.J., Creemers, E.E., Moerland, P.D., de Windt, L.J., van der Wal, A.C., Kok, W.E. & Pinto, Y.M. 2010. MiR423-5p as a circulating biomarker for heart failure. Circ Res 106, 1035–1039.
151. Tijsen, A.J., Pinto, Y.M. & Creemers, E.E. 2012. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol 303, H1085–H1095.
152. Towbin, J.A. & Bowles, N.E. 2002. The failing heart. Nature 415, 227–233.
153. Trimarco, B., De Simone, A., Cuocolo, A., Ricciardelli, B., Volpe, M., Patrignani, P., Sacca, L. & Condorelli, M. 1985. Role of prostaglandins in the renal handling of a salt load in essential hypertension. Am J Cardiol 55, 116–121.
154. Tsai, P.C., Liao, Y.C., Wang, Y.S., Lin, H.F., Lin, R.T. & Juo, S.H. 2013. Serum microRNA-21 and microRNA-221 as potential biomarkers for cerebrovascular disease. J Vasc Res 50, 346–354.
155. Tuccoli, A., Poliseno, L. & Rainaldi, G. 2006. miRNAs regulate miRNAs: coordinated transcriptional and post-transcriptional regulation. Cell Cycle 5, 2473–2476.
156. Turchinovich, A., Weiz, L., Langheinz, A. & Burwinkel, B. 2011. Characterization of extracellular circulating microRNA. Nucleic Acids Res 39, 7223–7233.
157. Valen, G., Yan, Z.Q. & Hansson, G.K. 2001. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38, 307–314.
158. Van Wagoner, D.R. & Nerbonne, J.M. 2000. Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol 32, 1101–1117.
159. Vickers, K.C., Palmisano, B.T., Shoucri, B.M., Shamburek, R.D. & Remaley, A.T. 2011. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13, 423–433.
160. Vickers, K.C., Rye, K.A. & Tabet, F. 2014. MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond) 126, 183–194.
161. Wang, G.K., Zhu, J.Q., Zhang, J.T., Li, Q., Li, Y., He, J., Qin, Y.W. & Jing, Q. 2010. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31, 659–666.
162. Ward, J.A., Esa, N., Pidikiti, R., Freedman, J.E., Keaney, J.F., Tanriverdi, K., Vitseva, O., Ambros, V., Lee, R. & McManus, D.D. 2013. Circulating cell and plasma microRNA profiles differ between non-ST-segment and ST-segment-elevation myocardial infarction. Fam Med Med Sci Res 2, 108.
163. Widera, C., Gupta, S.K., Lorenzen, J.M., Bang, C., Bauersachs, J., Bethmann, K., Kempf, T., Wollert, K.C. & Thum, T. 2011. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 51, 872–875.
164. Wright, J.T. Jr, Bakris, G.L., Bell, D.S., Fonseca, V., Katholi, R.E., McGill, J.B., Messerli, F.H., Phillips, R.A., Raskin, P., Holdbrook, F.K., Lukas, M.A. & Iyengar, M. 2007. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich) 9, 842–849.
165. Xie, W., Santulli, G., Guo, X., Gao, M., Chen, B.X. & Marks, A.R. 2013. Imaging atrial arrhythmic intracellular calcium in intact heart. J Mol Cell Cardiol 64, 120–123.
166. Xin, H., Li, Y., Cui, Y., Yang, J.J., Zhang, Z.G. & Chopp, M. 2013a. Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J Cereb Blood Flow Metab 33, 1711–1715.
167. Xin, H.Q., Li, Y., Liu, Z.W., Wang, X.L., Shang, X., Cui, Y.S., Zhang, Z.G. & Chopp, M. 2013b. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells 31, 2737–2746.
168. Xin, M., Olson, E.N. & Bassel-Duby, R. 2013c. Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. Nat Rev Mol Cell Biol 14, 529–541.
169. Xu, C.F., Yu, C.H. & Li, Y.M. 2009. Regulation of hepatic microRNA expression in response to ischemic preconditioning following ischemia/reperfusion injury in mice. OMICS 13, 513–520.
170. Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., Chen, G. & Wang, Z. 2007. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13, 486–491.
171. Zernecke, A., Bidzhekov, K., Noels, H., Shagdarsuren, E., Gan, L., Denecke, B., Hristov, M., Koppel, T., Jahantigh, M.N., Lutgens, E., Wang, S., Olson, E.N., Schober, A. & Weber, C. 2009. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2, ra81.
172. Zhao, Y., Samal, E. & Srivastava, D. 2005. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436, 214–220.
173. Zidar, N., Bostjancic, E., Glavac, D. & Stajer, D. 2011. MicroRNAs, innate immunity and ventricular rupture in human myocardial infarction. Dis Markers 31, 259–265.